Icon Genetics receives eu patent for its invention on norovirus-like particles with increased stability

Halle (Saale), 2. August 2023. Icon Genet­ics GmbH, a whol­ly owned sub­sidiary of Den­ka Co. Ltd, Tokyo, Japan, announced today that it has been grant­ed a Euro­pean patent (EP3938378B1) for its inven­tion on norovirus-like par­ti­cles with improved sta­bil­i­ty. The patent appli­ca­tion was filed on 11. March 2020 and grant­ed on 2. August 2023. The inven­tion pro­vides a way to increase the sta­bil­i­ty of VLPs derived from norovirus genogroup I strains to improve their usabil­i­ty in mul­ti­va­lent vac­cine com­po­si­tions where they are com­bined with more sta­ble VLPs from oth­er genogroups, e.g., genogroup II. The cre­ation of a mul­ti­va­lent vac­cine cov­er­ing all impor­tant norovirus genogroups and strains is impor­tant to obtain a broad­ly pro­tec­tive vac­cine against norovirus gas­troen­teri­tis.
Norovirus­es are respon­si­ble for approx­i­mate­ly 20% of all cas­es of acute gas­troen­teri­tis world­wide and are rec­og­nized as an impor­tant pub­lic health issue. There­fore, an effec­tive vac­cine is need­ed to reduce the glob­al bur­den of gas­troin­testi­nal dis­eases elicit­ed by it. Despite decades of inten­sive research in the field, no licensed vac­cine for pre­vent­ing norovirus dis­ease and ame­lio­rat­ing detri­men­tal health, soci­etal, and eco­nom­ic effects in all age groups is avail­able today.
The sta­ble norovirus genogroup I VLPs were already inves­ti­gat­ed as part of Icon Genet­ics norovirus vac­cine can­di­date in a suc­cess­ful phase I clin­i­cal study. Icon Genet­ics GmbH plans to fur­ther devel­op and com­mer­cial­ize its norovirus vac­cine and seeks col­lab­o­ra­tion with oth­er part­ners and stake­hold­ers for this pur­pose.